$25.16
0.39 (+1.57%)
Bristol-Myers Squibb Co. (BMY)
CAPS Rating:
The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.
RSS Headlines
Fool UK
Recs
The insiders are buying. The dividend is fat. They haven't eaten up another company like their bio/pharma bretheren (think PFE, MRK, Roche), so they don't have any rocky integrations to worry about. They have a stocked pipeline ( http://www.bms.com/research/pipeline/Pages/default.aspx).
Plus, we have a 1995 sale price. If you ever wanted to go back in time, well...